24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C
This study has been withdrawn prior to enrollment.
(Time elapsed to require permissions and a recent paper showed a high efficacy of a 48-week regimen in this setting. It seems non-ethical to start this trial)
Federico II University
Information provided by (Responsible Party):
Prof. Guglielmo Borgia, Federico II University
First received: January 17, 2012
Last updated: March 16, 2012
Last verified: March 2012
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
|Study Status:||This study has been withdrawn prior to enrollment.|
|Estimated Study Completion Date:||November 2015|
|Estimated Primary Completion Date:||November 2015 (Final data collection date for primary outcome measure)|